THYROTOXIC CARDIOMYOPATHY MANIFESTING AS HEART FAILURE WITH SUPRANORMAL EJECTION FRACTION: A CASE REPORT

Tạ Hoàng Lưu 1 , , Tạ Thắng Nam 1 , Trần Võ Trí Dũng 1 , Nguyễn Quốc Phòng 1 , Nguyễn Thị Kim Ngọc 1 , Võ Thảo Uyên 1 , Trần Hữu Chí 2 , Trần Thanh Vy 1, 2 , Nguyễn Thanh Huân 1, 2
1 University of Medicine and Pharmacy at Ho Chi Minh City image/svg+xml
2 Thong Nhat Hospital image/svg+xml
* Corresponding author:

Article Information

Metrics
Downloads: 10 Views: 28
DOI
10.63947/bvtn.v2i6.21
Published
2026-02-27
Issue Vol. 2 No. 6 (2026): Thách thức trong lão khoa 2026: Những giải pháp điều trị và chăm sóc toàn diện
Section
Case Report
Categories
Research

Download Article

PDF (Vietnamese)

How to Cite

1.
Hoàng Lưu T, Thắng Nam T, Võ Trí Dũng T, Quốc Phòng N, Thị Kim Ngọc N, Thảo Uyên V, Hữu Chí T, Thanh Vy T, Thanh Huân N. THYROTOXIC CARDIOMYOPATHY MANIFESTING AS HEART FAILURE WITH SUPRANORMAL EJECTION FRACTION: A CASE REPORT. JHA [Internet]. Vietnam; 2026 Feb. 27 [cited 2026 Mar. 15];2(6):141–146. https://tcsuckhoelaohoa.vn/bvtn/article/view/141 doi: 10.63947/bvtn.v2i6.21
Loading citation...
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Thyrotoxic cardiomyopathy is categorized within the spectrum of metabolic cardiomyopathies and typically presents with high-output heart failure accompanied by a supranormal left ventricular ejection fraction. In recent years, heart failure with supranormal ejection fraction (HFsnEF) has been increasingly regarded as a distinct heart failure phenotype, exhibiting worse prognosis and suboptimal treatment response compared with the group with preserved ejection fraction. In this report, we present a clinical case of a patient admitted with fatigue, palpitations, and diarrhea. After comprehensive integration of clinical findings, laboratory test results, and imaging data, the patient was ultimately diagnosed with thyrotoxicosis accompanied by heart failure with supranormal ejection fraction. The patient was treated with a combination of antithyroid medication and a beta-blocker. After seven days of therapy, the patient demonstrated marked improvement in clinical symptoms as well as cardiac function on echocardiographic assessment.

Keywords

cardiomyopathy heart failure supranormal ejection fraction thyrotoxic

References

  1. Quiroz-Aldave JE, del Carmen Durand-Vásquez M, Lobato-Jeri CJ, Muñoz-Moreno J-M, Condori DCDG, Ildefonso-Najarro SP, et al. Thyrotoxic cardiomyopathy: state of the art. 2023;19(1):78. DOI: https://doi.org/10.17925/EE.2023.19.1.78
  2. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? 2020;41(12):1249-57. DOI: https://doi.org/10.1093/eurheartj/ehz550
  3. Segev A, Ishay RT-B, Metra M, Maor E, Freimark D, Younis A, et al. Heart failure with supranormal ejection fraction: clinical characteristics and outcomes compared to mildly reduced and preserved ejection fraction. 2025;114(5):665-75. DOI: https://doi.org/10.1007/s00392-025-02620-9
  4. Ono R, Falcão LMJTAJoC. Supra-normal left ventricular function. 2023;207:84-92. DOI: https://doi.org/10.1016/j.amjcard.2023.08.169
  5. Horiuchi Y, Asami M, Ide T, Yahagi K, Komiyama K, Yuzawa H, et al. Prevalence, characteristics and cardiovascular and non‐cardiovascular outcomes in patients with heart failure with supra‐normal ejection fraction: Insight from the JROADHF study. 2023;25(7):989-98. DOI: https://doi.org/10.1002/ejhf.2895
  6. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. 2021;42(36):3599-726.
  7. Garg R, Prakash PJIJoCDiW. Heart Failure with Supranormal Ejection Fraction: A Female-Predominant Syndrome. 2025:1-10. DOI: https://doi.org/10.25259/IJCDW_109_2024
  8. Huang L, Feng J, Zhai M, Huang Y, Zhou Q, Zhang Y, et al. Clinical phenotypes of heart failure patients with supranormal ejection fraction. 2024;11(6):4160-71. DOI: https://doi.org/10.1002/ehf2.15021
  9. Chang HC, Huang WM, Lin LY, Lee CW, Tseng CH, Yu WC, et al. AU‐shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. 2025. DOI: https://doi.org/10.1002/ejhf.70061
  10. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. 2022;28(9):1956-64. DOI: https://doi.org/10.1038/s41591-022-01971-4
  11. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. 2016;26(10):1343-421. DOI: https://doi.org/10.1089/thy.2016.0229
  12. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SHJEtj. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. 2018;7(4):167-86. DOI: https://doi.org/10.1159/000490384
  13. Dahl P, Danzi S, Klein IJChfr. Thyrotoxic cardiac disease. 2008;5(3):170-6. DOI: https://doi.org/10.1007/s11897-008-0026-9
  14. Khan R, Sikanderkhel S, Gui J, Adeniyi A-R, O’Dell K, Erickson M, et al. Thyroid and cardiovascular disease: a focused review on the impact of hyperthyroidism in heart failure. 2020;11(2):68. DOI: https://doi.org/10.14740/cr1034

License

© 2026 The Author(s). Published by Journal of Health and Aging.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.